Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC lowered its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 68.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,700 shares of the biopharmaceutical company's stock after selling 30,300 shares during the period. Renaissance Technologies LLC's holdings in Xenon Pharmaceuticals were worth $537,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of XENE. FMR LLC raised its stake in shares of Xenon Pharmaceuticals by 8.8% during the fourth quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company's stock valued at $294,991,000 after acquiring an additional 607,606 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Xenon Pharmaceuticals by 1.3% in the 4th quarter. Alliancebernstein L.P. now owns 1,443,180 shares of the biopharmaceutical company's stock valued at $56,573,000 after buying an additional 18,445 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Xenon Pharmaceuticals by 38.9% during the fourth quarter. JPMorgan Chase & Co. now owns 1,356,895 shares of the biopharmaceutical company's stock worth $53,190,000 after acquiring an additional 380,112 shares during the last quarter. TimesSquare Capital Management LLC increased its position in Xenon Pharmaceuticals by 9.1% during the 4th quarter. TimesSquare Capital Management LLC now owns 848,850 shares of the biopharmaceutical company's stock valued at $33,275,000 after purchasing an additional 70,557 shares during the period. Finally, Jennison Associates LLC increased its position in shares of Xenon Pharmaceuticals by 39.0% during the fourth quarter. Jennison Associates LLC now owns 801,553 shares of the biopharmaceutical company's stock worth $31,421,000 after buying an additional 224,892 shares during the period. Institutional investors own 95.45% of the company's stock.

Xenon Pharmaceuticals Price Performance

XENE stock traded down $0.10 during trading on Friday, hitting $35.44. 502,618 shares of the company traded hands, compared to its average volume of 469,435. Xenon Pharmaceuticals Inc. has a 1 year low of $26.74 and a 1 year high of $46.00. The stock's 50-day simple moving average is $34.61 and its 200 day simple moving average is $38.38. The company has a market cap of $2.71 billion, a PE ratio of -12.57 and a beta of 1.21.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.05. Research analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on XENE. The Goldman Sachs Group dropped their price objective on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. StockNews.com lowered Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, May 2nd. Chardan Capital initiated coverage on shares of Xenon Pharmaceuticals in a report on Wednesday. They issued a "buy" rating and a $55.00 price target on the stock. Royal Bank of Canada reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. Finally, William Blair reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Monday. One analyst has rated the stock with a sell rating and eleven have issued a buy rating to the stock. According to MarketBeat, Xenon Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $56.60.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.